|
| Jasmonate | Drug conc. range/vehicle | Model | Effects | References |
|
(1) MJ + BCNU (nitrosourea)
in vitro | MJ: Fixed conc.
| Pancreatic MIA PaCa-1
| Mitochondriotoxic
synergic cytotoxicity
|
[170] |
(2) MJ + 2DG,
adriamycin, taxol, BCNU or cisplatin
in vitro | MJ: 0.5–2.0 mM/EtOH
Taxol, cisplatin: 1–10 µg/mL | CT26, DA-3, GTRAMP C1, MCF7, MIA PaCa-2, D122, and BCL1
| Strong cooperative
effects of MJ + 2DG
and MJ + other drugs
|
(3) MJ + adriamycin
in vivo | MJ i.v.: 20–150 mg/kg dissolved in lipofundin.
Adr (DOX) i.p.:
4 mg/kg | Balb/c mice injected i.p. with 1 × 104 chronic BCL1 cells lymphocyte leukemia cells | MJ + Adr: significant prolonged survival effect |
|
(4) MJ + PI3K/Akt inhibitors
in vitro | MJ: 0.5–3.0 mM
EtOH/DMSO | Sarcoma MCA-105, SaOS-2
| ↓MJ-induced activation of Akt ↑synergic cytotoxicity
|
[49] |
(5) MJ + 2DG
in vitro | MJ: 0.5–3.0 mM
EtOH/DMSO | Sarcoma MCA-105, SaOS-2 | 2DG: ↓pAkt, ↓MJ-ind. pAkt
MJ + 2DG: ↑synergic cytotoxicity |
|
(6) MJ + irradiation
in vitro | 0.5–2.0 mM
DMSO | Irradiated prostate PC-3 (radiation induces Bcl-2 expression) | ↓radiation-induced Bcl-2
↑radiation sensitivity PC-3
↑caspase-3 | [104] |
|
(7) MJ and/or POH and/or
cis-platin (CP)
in vitro |
Both tested
at IC20 | Human MDA-MB-435
[74] | MJ + POH: ↑TNFR1 ↓Δ ↑cytotoxicity; cell cycle arrest at G0/G1↑apoptosis
+ CP: all effects enhanced |
[251] |
Human breast
MDA-MB-231 | ↑apoptosis |
|
(8) MJ + TRAIL
in vitro | MJ 0.5 mM + TRAIL (100–200 ng·mL−1) | CRC cancer cells | ↓survivin (IAP)
↓Wnt/TCF pathway
↑TRAIL-induced apoptosis
↑caspase activity | [32] |
|
(9) MJ + Smac
in vitro |
MJ: 0.5–2.0 mM DMSO | Human bladder cancer EJ, T24 | Synergy: ↑IAPs-bound caspase 3 ↑apoptosis |
[254] |
| Human embryonic kidney HEK 293 | No cytotoxicity |
|
(10) MJ + Smac7N (IAP antagonist)
in vitro | MJ: 0.5–2.0 mM DMSO | Hormone-independent prostate DU-145, PC-3
Human proximal tubular epithelial HK-2 cells (overexpressing IAPs) | Smac7N: ↑MJ-induced apoptosis by caspase-9-dependent (intrinsic) and independent (extrinsic) pathways | [255] |
|
(11) MJ + cisplatin (0.1–0.5 μM)
MJ + X-rays
(0.25–3 Gy)
MJ + -rays | MJ: 0.1–1.0 mM EtOH | Cervical cancer cells
SiHa, CaSki, HeLa, and C33A | ↓ viability
↓survival
↓IC50 radiation dose | [29] |
|
(12) MJ + 5-FU
in vitro | 0.5 mM MJ/1 h, then + 5-FU | Human adenocarcinoma
colon HT-39 | ↓IC50 5-FU (5 → 2.5 mM) | [31] |
|
